JULIANNA DAVIS: Open Payments
NPI 1871000323 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$765 in 48 payments from 9 companies in 2025. Trend: 2023 $846 · 2024 $384 · 2025 $765
Food & beverage: $756Education: $10
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 11 | $280 |
| ABBVIE INC. | 22 | $190 |
| GENZYME CORPORATION | 4 | $140 |
| Kerecis Limited | 2 | $54 |
| Organogenesis Inc. | 2 | $31 |
| Organon LLC | 4 | $22 |
| Botanix SB Inc | 1 | $19 |
| Galderma Laboratories, L.P. | 1 | $15 |
| Arcutis Biotherapeutics, Inc. | 1 | $14 |
Products named: TREMFYA, DUPIXENT, SKYRIZI, RINVOQ, Kerecis SurgiClose, VIA MATRIX, SOFDRA, NEMLUVIO.
Industry payments across PA — which companies pay providers there.
